Methods and formulations for use in treating oophorectomized women
US5340586A · kind A · utility
115Cited by
6References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 1993 |
| Grant date | Aug 23, 1994 |
| Priority date | — |
| Expiry date | May 17, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0036
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods which are effective to prevent symptoms of loss of ovarian function (e.g., in oophorectomized women) over a period of time are described, consisting essentially of an effective amount of an estrogenic composition and an effective amount of an androgenic composition. The levels of estrogens and androgens employed are sufficient to reduce bone mineral density loss and minimize other side effects observed after oophorectomy, and at such low doses as to minimize any adverse impact on the patient's long-term prognosis or (in the case of testosterone) result in additional side effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.